Article Text

Download PDFPDF
One-step closer to solve the mystery of predicting disease progression in systemic sclerosis associated interstitial lung disease?
  1. Anna-Maria Hoffmann-Vold1,
  2. Michael Kreuter2,3
  1. 1Department of Rheumatology, Oslo University Hospital, Oslo, Norway
  2. 2Centre of Interstitial and Rare Lung, Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
  3. 3German Center for Lung Research (DZL), Heidelberg, Germany
  1. Correspondence to Dr Anna-Maria Hoffmann-Vold, Rheumatology, Oslo University Hospital, Oslo 0372, Norway; a.m.hoffmann-vold{at}medisin.uio.no

Statistics from Altmetric.com

Interstitial lung disease (ILD) is a frequent organ manifestation in systemic sclerosis (SSc) and is associated with high morbidity and mortality.1 The severity and disease course vary widely from mild and stable disease to severe and rapidly progressing.2 Early detection of ILD and prediction of disease progression are key in the management of SSc-ILD, as any ILD in SSc is associated with reduced long-term outcome especially in case of disease progression.1 There has been substantial progress in the treatment of this devastating condition, but allocation of the right treatment at the right time for any given individual with SSc-ILD remains challenging. While several risk factors for ILD progression in SSc have been identified in the past, the predictive ability of single factors is very moderate.3 Combination of different risk factors such as early disease, increased inflammatory markers, recent skin progression and the diffuse cutaneous SSc subset have been shown to improve the identification of patients at risk of progression.3 However, a high unmet need still exists to specifically identify the individual patient with SSc-ILD who is at risk of progressive disease, to initiate treatment early, to prevent progression and to avoid irreversible …

View Full Text

Footnotes

  • Contributors Both authors conceptualised, discussed and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles